Pancreatic Cancer Cell Death Triggered by Caspase‑8 Blockade in Preclinical Models
Researchers at the University of Cologne have identified that blocking the protein caspase-8 can trigger programmed cell death in KRAS-mutant pancreatic cancer cells. This discovery reveals a potential vulnerability that could lead to new therapeutic strategies for the lethal disease.
Why it matters
Identifying new molecular targets for pancreatic cancer is critical for improving survival rates in one of the most difficult-to-treat malignancies.
Pancreatic cancer remains one of the most lethal malignancies, notorious for its late detection, rapid progression, and stubborn resistance to many therapeutic strategies clinicians have tried. Despite decades of effort, standard treatments have delivered only incremental gains, and the disease is projected to become the second leading cause of cancer‑related death within this decade. Now, researchers at the University of Cologne’s Center for Molecular Medicine Cologne (CMMC) have uncovered a surprising vulnerability in KRAS‑mutant pancreatic tumors—one that primes them for a potent form of programmed cell death.
The article is a technical summary of scientific research published in a peer-reviewed journal.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in